Evidence map›Paper›PMID 28149842›Full record

ArticleAnnals of translational medicine2016

Inertia based microfluidic capture and characterisation of circulating tumour cells for the diagnosis of lung cancer.

Dimple Y Chudasama, Daria V Freydina, Maxim B Freidin, Maria Leung, Angeles Montero Fernandez, Alexandra Rice, Andrew G Nicholson, Emmanouil Karteris, Vladimir Anikin, Eric Lim

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. SimultaneousAnnals of translational medicine · 2021
    Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Dimple Y ChudasamaNational Heart and Lung Institute, Imperial College London, London, UK;; Division of Thoracic Surgery, Harefield Hospital, The Royal Brompton and Harefield Hospitals NHS Foundation Trust, London, UK;; Division of Biosciences, Brunel University London, London, UK.
Daria V FreydinaNational Heart and Lung Institute, Imperial College London, London, UK;; Academic Division of Thoracic Surgery, The Royal Brompton and Harefield Hospitals NHS Foundation Trust, London, UK.
Maxim B FreidinNational Heart and Lung Institute, Imperial College London, London, UK;; Academic Division of Thoracic Surgery, The Royal Brompton and Harefield Hospitals NHS Foundation Trust, London, UK.
Maria LeungNational Heart and Lung Institute, Imperial College London, London, UK;; Academic Division of Thoracic Surgery, The Royal Brompton and Harefield Hospitals NHS Foundation Trust, London, UK.
Angeles Montero FernandezNational Heart and Lung Institute, Imperial College London, London, UK;; Department of Histopathology, The Royal Brompton and Harefield Hospitals NHS Foundation Trust, London, UK.
Alexandra RiceNational Heart and Lung Institute, Imperial College London, London, UK;; Department of Histopathology, The Royal Brompton and Harefield Hospitals NHS Foundation Trust, London, UK.
Andrew G NicholsonNational Heart and Lung Institute, Imperial College London, London, UK;; Department of Histopathology, The Royal Brompton and Harefield Hospitals NHS Foundation Trust, London, UK.
Emmanouil KarterisDivision of Biosciences, Brunel University London, London, UK.
Vladimir AnikinDivision of Thoracic Surgery, Harefield Hospital, The Royal Brompton and Harefield Hospitals NHS Foundation Trust, London, UK.
Eric LimNational Heart and Lung Institute, Imperial College London, London, UK;; Academic Division of Thoracic Surgery, The Royal Brompton and Harefield Hospitals NHS Foundation Trust, London, UK.
Imperial College London · GBHarefield Hospital · GBBrunel University of London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRoutine clinical application of circulating tumour cells (CTCs) for blood based diagnostics is yet to be established. Despite growing evidence of their clinical utility for diagnosis, prognosis and treatment monitoring, the efficacy of a robust platform and universally accepted diagnostic criteria remain uncertain. We evaluate the diagnostic performance of a microfluidic CTC isolation platform using cytomorphologic criteria in patients undergoing lung cancer surgery.

methodsBlood was processed from 51 patients undergoing surgery for known or suspected lung cancer using the ClearBridge ClearCell FX system

resultsCancer was diagnosed in 43.1% and 54.9% of all cases. In early stage primary lung cancer, between the two reporting teams, a positive diagnosis of CTCs was made for 50% and 66.7% of patients. The agreement between the reporting teams was 80.4%, corresponding to a kappa-statistic of 0.61±0.11 (P<0.001), indicating substantial agreement. Sensitivity levels for the two teams were calculated as 59% (95% CI, 41-76%) and 41% (95% CI, 24-59%), with a specificity of 53% for both.

conclusionsThe performance of the tested microfluidic antibody independent device to capture CTCs using standard cytomorphological criteria provides the potential of a diagnostic blood test for lung cancer.

Indexed as

Circulating tumour cells (CTCs)ClearBridgelung cancer

Identifiers

PMID28149842
PMCPMC5233537
OpenAlexW2569049196

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.